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Haemostasis in Patients with Behc¸et’s Disease
S. Demirer1, N. S¸engu¨l1, M. A. Yerdel1, A. Tu¨zu¨ner1, A. T. Ulus3, A. Gu¨rler2, D. Bergqvist3, A. Siegbahn1
and S. Karacagil∗2
Departments of 1Surgery and 2Dermatology, Ankara University Hospital, Turkey; and Departments of 3Surgical and
4Medical Sciences, University Hospital, Uppsala, Sweden
Aim: to determine whether Behc¸et’s disease affects haemostatic function.
Setting: University Hospital, Turkey.
Patients: one hundred and twenty-seven consecutive patients with Behc¸et’s disease, 34 of whom with a history of vascular
involvement.
Methods: prothrombin fragment 1+2 tissue plasminogen activator, protein S and C, antithrombin, fibrinogen, von
Willebrand factor, thrombomodulin and prothrombin time (PT) were measured in patient plasma.
Results: soluble thrombomodulin was significantly lower and von Willebrand factor (vWF) and tissue plasminogen
activator (tPA) significantly higher in Behc¸et’s patients. Patients with vascular involvement showed the highest levels of
vWF and tPA. There was no activation of coagulation, not even in patients with an active disease at the time of sampling.
Conclusion: there were indirect signs of endothelial activity or damage, particularly in patients with vascular involvement.
Coagulation was not activated.
Introduction present study was, therefore, to assess several haemo-
static functions, in 127 patients with Behc¸et’s disease
Although the aetiology of Behc¸et’s disease remains an and in 24 healthy controls.
enigma, progress has been made since the Turkish
dermatologist Hulusi Behc¸et reported it in 1937.1 The
typical manifestations comprise the clinical triad of
recurrent oral and genital ulceration and relapsing
Patients and Methodsuveitis. It is now recognised as a multisystemic chronic
inflammatory disorder that may include neurologic,
A total of 127 consecutive patients visiting the de-cardiovascular, pulmonary, gastrointestinal, uro-
partments of surgery and dermatology, Ankara Uni-genital and musculoskeletal involvement.2–4
versity Hospital, 34 (27%) with a history of vascularVascular system involvement is well recognised. The
involvement, all fulfilling the criteria of the Inter-disease may affect both arteries and veins with lesions
national Study Group for Diagnosis of Behc¸et’s Dis-ranging from superficial thrombophlebitis to occlusion
ease, were included in the study.6 Twenty-four healthyof the vena cava and occlusion, as well as aneurysm
unrelated individuals were investigated for com-formation, in the arterial system.2,3 Microscopy has
parison. They had no history of vascular disease.identified vasculitis in both veins and arteries, but
Patient characteristics are given in Table 1. Patientsthe aetiology remains obscure. Although it has been
with vascular involvement were further divided intosuggested that haemostatic abnormalities might be
those with venous and those with arterial involvement.responsible for the vascular pathology, their specific
Among 30 patients with venous involvement, 23 hadrelation to Behc¸et’s disease is still controversial.5 There
deep-vein thrombosis of the lower extremity, five hadare several case reports on various haemostatic al-
superficial lower-extremity thrombophlebitis and twoterations, but due to the rare occurrence of the disease
had superior vena caval thrombosis. Among fourvirtually no systematic studies exist. The aim of the
patients who had arterial involvement, two had as-
sociated deep-venous thrombosis of the lower ex-
tremity. Arterial lesions in the four patients were one∗ Please address all correspondence to: S. Karacagil, Department of
Surgery, University Hospital, Uppsala, SE-751 85, Sweden. iliofemoral artery thrombosis, one isolated common
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Table 1. Patient characteristics according to Behc¸et’s disease with and without vascular involvement and control
group.
Behc¸et without vasculitis Behc¸et with vasculitis Control
(n=93) (n=34) (n=24)
Sex:
Male 35.5% (33) 76.5% (26) 41.7% (10)
Female 64.5% (60) 23.5 (8) 58.3% (14)
Age, years 36.8±9.8 36.4±7.7 27.1±4.9∗
Clinically active 62.4% (58) 61.8% (21) —
Smoking 24.7% (23) 44.1% (15) 50% (12)∗
Complication:
Venous — 88.2% (30) —
Arterial — 11.8% (4) —
Duration of Behc¸et 8.2±4.9 9.4±5.3 —
Duration of Vasculitis — 4.2±3.4 —
Behc¸et:
Immuno 100% (4) (0) —
Entero 100% (2) (0) —
Pulmonary (0) 100% (2) —
Ocular 60% (12) 40% (8) —
Articular 83.9% (26) 16.1% (5) —
∗ p<0.05.
iliac artery aneurysm, and two abdominal aortic an- Thrombomodulin was assessed using an enzyme
immunoassay (Diagnostica Stago, Asnie`res, France).eurysms associated with iliac aneurysm in one and
femoral artery aneurysm in the other. Reference value 33±7 ng/ml.
PT was measured with Nycotest PT (NycomedSeventy-nine (62.2%) patients had active clinical pre-
sentation at the time of blood sampling, which was Pharma, Oslo, Norway) and INR calculated. Reference
value 70–130%.determined as recurrence of at least one major or
minor symptom. The others had no sign of ongoing Values were expressed as mean±standard de-
viation. Categorical group differences were soughtactivity.
Blood was sampled in the following manner: 9 ml using the Chi-squared or Fisher’s exact test, Student’s
t-test was used to compare the differences betweenin 1 ml of citrate 0.129 M (Becton Dickinson, Vacutainer
Systems Eur. B.P. 3738241 Myelan Cedex, France), the groups. The measurements in these groups were
compared using an analysis of variance (ANOVA).centrifuged for 10 minutes at 2000×g and frozen in 5
tubes in −70 °C until analysis. p-Value less than 0.05 was considered statistically sig-
nificant.Prothrombin-fragment 1+2 (F1+2) was measured
by ELISA (Enzygnost Behringerwerke AG, Marburg,
Germany). Reference value 0.4–1.5 nmol/l.
Tissue plasminogen activator antigen (tPA) was Results
quantified with an enzyme immunoassay (Imulyse
tPA, Biopool, Umea˚, Sweden). Reference value The mean age of the patients in the Behc¸et group was
36.7±9.3 years compared to 27.1±4.9 years in the3–10 ng/ml.
Protein S and C were measured using an enzyme control group (p<0.05). In the vasculo-Behc¸et group
76.5% of the patients (26/34) were males comparedimmunoassay (Asserachrom, Diagnostica Stago, As-
nie`res, France) and a colorimetric method (STAChrom, with 35.5% (33/93) and 41.7% (10/24) in non-vasculo-
Behc¸et and control groups (p<0.05). Smoking wasDiagnosticastago, Asnie`res, France) respectively. Ref-
erence values 7–130%. found in 29.9% in the Behc¸et group and 50% in the
control group (p>0.05) (Table 1). The mean durationAntithrombin was measured with the Coamatic LR
Antithrombin test (Chromogenix, Mo¨lndal, Sweden). of Behc¸et’s disease was 8.5±5.0 years (0.5–22 years).
The mean duration of vascular involvement wasReference value 104±18%.
Fibrinogen was analysed by rate nephelometry with 4.2±3.4 years (0.25–12 years).
PT and INR values were 12.2±2.0 and 1.2±0.6 ina Beckman Array protein system (Beckman In-
struments). Reference value 2.0–3.6 g/l. the Behc¸et group, 12.6±0.9 and 1.0±0.1 in the control
group (p>0.05). There was no significant differencevon Willebrand factor was measured using an en-
zyme immunoassay (Asserachrom vWF, Diagnostica between the groups regarding protein C, S and anti-
thrombin levels (Table 2). Protein C was 99.2±25.5 inStago, Asnie`res, France). Reference value 50–160%.
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Table 2. Haemostatic values in Behc¸et and control groups.
Behc¸et (127) Control (24)
Protein C (% act) 99.2±25.5 87.2±27.8
Protein S (% act) 87.8±22.6 92.7±19.4
Antithrombin (% act) 108.5±19.9 100.9±10.5
Fibrinogen (g/l) 4.2±1.37 3.7±0.91
PT (sec) 12.2±2.0 12.6±0.9
INR 1.2±0.6 1.0±0.1
vWF (%) 108.9±40.2∗ 88.2±30.7
Thrombomodulin (ng/ml) 19.0±10.3∗ 25.9±10.9
Prothrombin fragment 1+2 (nmol/l) 0.79±1.01 0.97±1.5
tPA (ng/ml) 7.72±3.58∗ 5.25±1.84
∗ p<0.05.
Table 3. Haemostatic values in Behc¸et patients with and without vascular involvement and control group.
Behc¸et without vasculitis Behc¸et with vasculitis Control
(n=93) (n=34) (n=24)
Protein C (% act) 98.8±24.6 100.1±27.8 87.2±27.8
Protein S (% act) 90.1±19.5 81.9±28.6 92.7±19.4
Antithrombin (% act) 108.3±19.6 109.1±20.9 100.9±10.5
Fibrinogen (g/l) 4.2±1.27 4.3±1.63 3.7±0.91
PT (sec) 12.1±2.3 12.5±1.3 12.6±0.9
INR 1.2±0.7 1.2±0.2 1.0±0.1
vWF (%) 104.3±32.4 121.8±54.8∗ 88.2±30.7
Thrombomodulin (ng/ml) 17.9±9.7 21.9±11.3 25.9±10.9
Prothrombin fragment 1+2 (nmol/l) 0.79±1.14 0.83±0.91 0.98±1.52
tPA/ng/ml 7.57±3.81∗ 8.16±2.89∗ 5.25±1.84∗
∗ p<0.05.
the Behc¸et group and 87.2±27.8 in the control group (5.8±2.47 g/l vs. 4.1±1.43 g/l, p<0.05) (Table 4). There
were no significant differences with regard to other(p>0.05). Although the fibrinogen value was not
haematological variables between the arterial and ven-statistically different, it was numerically higher in
ous groups. Thrombomodulin values were sig-the Behc¸et group, 4.2±1.57 g/l compared with
nificantly lower in clinically active Behc¸et patients3.7±0.91 g/l in the control group. The von Willebrand
compared to those without active lesionsfactor and thrombomodulin levels were considerably
(17.3±6.6 ng/ml and 22.1±13.3 ng/ml, p<0.05) (Tabledifferent in the Behc¸et group. They were 108.9±40.2
5).and 19.0±10.3 ng/ml in the Behc¸et group, 88.2±30.7
and 25.9±10.9 ng/ml in the control group (p<0.05)
(Table 2). tPA was also significantly higher in the
Behc¸et group.
von Willebrand factor level was significantly higher Discussion
in Behc¸et patients with vascular involvement
(121.8±54.8) compared with both controls (88.2±30.7) Behc¸et’s disease is a multisystem, relapsing chronic
and patients without vascular disease (104.3±32.4). disorder of unknown aetiology. Immunological, in-
tPA was also highest in the vasculo-Behc¸et group. All cluding autoimmune and viral, causes and an HLA-
the other parameters were similar between the groups related immunogenetic predisposition have been sug-
(Table 3). gested as causative factors.5,7–15 Histopathological non-
Fibrinogen level was significantly higher in patients specific vasculitis of the veins, arteries and capillaries
are common to all involved organs. Vasculitic lesionswith arterial rather than venous involvement
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Table 4. Haematological values in Behc¸et patients with arterial and venous involvement.
Vasculitis with arterial Vasculitis with venous
problems (4) problems (30)
Protein C (% act) 108.5±15.9 98.9±29.0
Protein S (% act) 87.5±29.6 81.1±28.9
Antithrombin (% act) 101.3±20.2 110.2±21.2
Fibrinogen (g/dl) 5.8±2.47 4.1±1.43∗
PT (sec) 11.8±0.5 12.5±1.3
INR 1.1±0.1 1.2±0.3
vWF (%) 151.0±44.3 117.9±55.5
Thrombomodulin (ng/ml) 32.0±13.5 20.5±10.4
Prothrombin fragment 1+2 (nmol/l) 0.83±0.97 0.80±0.31
tPA (ng/ml) 8.38±2.93 6.47±2.21
∗ p<0.05.
Table 5. Haematological values according to presence of clinically active lesions in Behc¸et group.
Behc¸et group Clinically active (79) Clinically inactive (48)
Protein C (% act) 99.0±26.3 102.9±26.5
Protein S (% act) 87.9±21.5 83.9±28.3
Antithrombin (% act) 110.8±18.4 11.8±19.8
Fibrinogen (g/l) 4.1±1.30 4.4±1.54
PT (sec) 12.3±1.6 11.9±1.3
INR 1.2±0.3 1.1±0.3
vWF (%) 110.9±39.9 110.3±44.9
Thrombomodulin (ng/ml) 17.3±6.6 22.1±13.3∗
Prothrombin fragment 1+2 (nmol/l) 0.91±1.45 0.72±0.28
tPA (ng/ml) 7.61±3.63 8.26±3.79
∗ p<0.05.
are characterised by perivascular lymphocyte and the Behc¸et groups regarding plasma protein C, S and
antithrombin levels. By contrast, thrombomodulinmononuclear cell infiltration, endothelial oedema, de-
generation at the elastic lamina interna and fibrinoid levels were significantly lower in the Behc¸et group;
those with clinically active disease had significantlynecrosis, deposition of immune complex at the vas-
cular wall.16 lower levels still. It has been suggested that a low
thrombomodulin level in combination with factor VVascular involvement is one of the most important
features, has been reported in 7–29% of patients, and Leiden mutation increases the risk for thrombotic com-
plications.25 There were no significant differences withaccounts for most of the deaths.2,3,17,18 Vascular lesions
consist of venous and arterial thrombosis and various regard to thrombomodulin levels in subgroups of
Behc¸et patients such as vasculo-Behc¸et, arterial ortypes of arterial aneurysms. Although involvement of
all types and sizes of blood vessels may occur, lower venous involvement.
Significantly higher plasma concentrations of vWf-extremity deep and superficial venous thrombosis pre-
dominates.2,3,17,18 Very little is known about haemostasis related antigen have been previously reported in
patients with Behc¸et’s disease, and confirmed in thein patients with Behc¸et’s disease. Previous reports have
produced contradictory results. present study. It may be speculated that a consumption
and/or leakage phenomenon from the damaged endo-Protein C, protein S and antithrombin deficiencies
are known to predispose to thrombotic events.19–21 thelial cells cause the elevated levels of vWF and
tPA.19–21,26–28 Furthermore, vasculo-Behc¸et patients haveNalcaci et al.22 and Lenk et al.23 did not find any protein
C, S and antithrombin abnormalities in 35 and 25 significantly higher vWf and tPA values compared to
those without vascular involvement. There seems toBehc¸et patients, respectively. Chafa et al.4 and Guer-
mazi et al.24 reported a protein S deficiency in patients be an indication that the more severe the vascular
involvement, the higher are the vWF and tPA levels.with Behc¸et’s disease but observed normal protein C
levels. The present study, which is the largest to date, Fibrinogen levels were higher, although not sig-
nificant, in Behc¸et patients and especially in thosealso revealed no difference between the control and
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